Skip to main content
OpenTrials
Completed

NCT Number: NCT06892119

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation

Generic plerixafor use at reduced-dose for mobilization on HSCT transplant

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoproliferative Disorders Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Universidad Autónoma de Nuevo León

Monterrey, Nuevo León, 64460, Mexico

About this study

The objective of this study is to demonstrate that the use of a low dose of the generic form of a drug called plerixafor is effective in increasing the amount of hematopoietic cells (stem cells) in your blood, which will then be collected for your transplant. Plerixafor is a very effective medicine that is already used for this purpose, however its high cost limits its use in all patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with lymphoma or multiple myeloma who are candidates for autoHSCT
  • Patients > 18 years old who signed our informed consent
  • Normal CBC count (Hb > 10, WBC 4.0-11.00, plt > 100,000)

Exclusion criteria

  • Patients with HIV, Hepatitis C, Hepatitis B diagnosis
  • Pregnant women

Treatment and study plan

Celrixafor

Drug

Use a reduced-dose of generic plerixafor

Primary outcomes

  1. Post-RD plerixafor increase in CD34+/μL pre-count, final CD34+ cell yield and harvest

    Time frame: 1 year

    The objective of this study is to demonstrate that the use of a low dose of the generic form of plerixafor is effective in increasing the amount of hematopoietic cells (stem cells).

Sponsors and collaborators

Lead sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Other

Registry information

Official study title

Dose-reduced Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Patients With Lymphoma and Myeloma

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Mar 24, 2025
Registry last updated
Mar 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.